Management of Elevated White Blood Cell Count

Initial Assessment and Treatment

The American College of Physicians recommends determining the severity and context of leukocytosis, with hyperleukocytosis (>100,000/μL) representing a medical emergency due to risk of brain infarction and hemorrhage from leukostasis 2

For inflammatory conditions, the National Comprehensive Cancer Network recommends addressing the primary inflammatory process 2
For hyperleukocytosis (>100,000/μL), aggressive IV hydration with 2.5-3 liters/m²/day is required to prevent tumor lysis syndrome and maintain renal perfusion 2
Hydroxyurea at 50-60 mg/kg/day can rapidly reduce WBC count to <10-20 × 10⁹/L 1, 2
Leukapheresis should be considered only for symptomatic leukostasis in non-APL cases 1, 2

For Acute Myeloid Leukemia (AML), induction chemotherapy with anthracycline plus cytarabine should be initiated after WBC reduction 1, 2
For Acute Promyelocytic Leukemia (APL), all-trans retinoic acid (ATRA) should be started immediately upon suspicion, and leukapheresis should never be performed due to risk of fatal hemorrhage 1, 2, 3
Platelets should be maintained >30-50 × 10⁹/L and fibrinogen >100-150 mg/dL in APL patients 1

The National Comprehensive Cancer Network recommends obtaining blood cultures before starting antibiotics in patients with chemotherapy-induced neutropenia 1
G-CSF use should be selective, reserving it for high-risk patients, and not used routinely with fever 1
Antifungal prophylaxis with posaconazole can decrease fungal infections compared to fluconazole in high-risk patients 1, 3
Azole antifungals should be avoided during anthracycline chemotherapy due to impaired drug metabolism and increased toxicity 1, 3

Definitive therapy in acute leukemia should not be delayed after initial WBC reduction, with prompt chemotherapy being essential 1, 2
Leukapheresis should not be used in APL due to risk of fatal hemorrhage 1, 2, 3